Similar articles

• Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).

  Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Hertel J, et al. Am J Nephrol. 2006;26(2):149-56. doi: 10.1159/000092852. Epub 2006 Apr 21. Am J Nephrol. 2006. PMID: 16636531 Clinical Trial.
• [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].

  Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F. Martínez Castelao A, et al. Nefrologia. 2003;23(2):114-24. Nefrologia. 2003. PMID: 12778875 Clinical Trial. Spanish.
• Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.

  Doshi S, Chow A, Pérez Ruixo JJ. Doshi S, et al. J Clin Pharmacol. 2010 Sep;50(9 Suppl):75S-90S. doi: 10.1177/0091270010377201. J Clin Pharmacol. 2010. PMID: 20881221
• Darbepoetin alfa: a new therapy for the management of anaemia associated with chronic kidney disease.

  Lindberg J. Lindberg J. Expert Opin Biol Ther. 2002 Dec;2(8):977-84. doi: 10.1517/14712598.2.8.977. Expert Opin Biol Ther. 2002. PMID: 12517275 Review.
• Darbepoetin alfa for the treatment of cancer-related anemia: an update.

  Pirker R. Pirker R. Expert Rev Anticancer Ther. 2004 Oct;4(5):735-44. doi: 10.1586/14737140.4.5.735. Expert Rev Anticancer Ther. 2004. PMID: 15485310 Review.